pISSN 1226-6329 / eISSN 2733-4600
대한노인정신의학회 (13권1호 44-48)
An Open Label Study of Mirtazapine in the Treatment of Depression with Alzheimer＇s Dementia
알츠하이머 치매 환자에 동반된 우울증상의 치료에 관한 Mirtazapine의 효과와 안정성에 대한 개방 연구
최하나(Hana Choi);임현국(Hyun Kook Lim);이철(Chul Lee);이창욱(Chang Uk Lee)
Depression is one of the most devastating behavioral symptoms in demented patients but there is little evidence about effective and safe pharmacotherapy. We aimed to determine the effectiveness and safety of mirtazapine in treatment of depressed patients with Alzheimer＇s disease (AD). The consecutive patients with AD who have significant depression were assigned to an 8-week open-label, prospective study. Patients received mirtazapine 15-45 mg/day. The changes in Hamilton Depression Rating Scale (HAM-D) scores were primary outcome measurement. The change in Clinical Global Impression-Severity scale (CGI-S) scores and tolerability-safety profile were the secondary efficacy variables. Thirty-two out of 38 (84.2%) patients completed the study. There was a significant reduction in HAM-D and CGI-S between the pre- and post-treatment with mirtazapine (p<0.01). There was no significant side effect and cognitive deterioration. The results of this open-label pilot study suggest that mirtazapine may be an effective choice for treatment of depressed patients with AD.
우울증,알츠하이머 치매, Mirtazapine,Depression,Alzheimer＇s dementia
PDF